TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22717198

Group type: EXPERIMENTAL
Intervention: Comprehensive nutrition and lifestyle educational intervention (n=72)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Noncomprehensive approach (comparison group n=72)
Number of subjects: 144
Study: 20526718

Group type: EXPERIMENTAL
Intervention: Intravenous amoxicillin plus clavulanic acid 1 g every 8 h followed by oral antibiotic after improvement and discharge the next day.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intravenous amoxicillin plus clavulanic acid for 7 days followed by oral antibiotic at discharge.
Number of subjects: 50
Study: 19127910

Group type: EXPERIMENTAL
Intervention: Acupuncture plus medication (routine western medicine)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Medication (routine western medicine)
Number of subjects: 60
Study: 16721316

Group type: EXPERIMENTAL
Intervention: Short course of family-based therapy (FBT)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Long course of family-based therapy (FBT)
Number of subjects: 86
Study: 12794603

Group type: EXPERIMENTAL
Intervention: Unidimensional measurement technique
Number of subjects: 86

Group type: COMPARATOR
Intervention: Bidimensional measurement technique
Number of subjects: 86
Study: 11140151

Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiation (group 1, n = 9)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiation (group 2, n = 5)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiation (group 1, n = 6)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiation (group 2, n = 4)
Number of subjects: 14
Study: 9001838

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg/benazepril 20 mg
Number of subjects: 308

Group type: COMPARATOR
Intervention: Amlodipine 5 mg
Number of subjects: 308

Group type: COMPARATOR
Intervention: Benazepril 20 mg
Number of subjects: 308

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 308
Study: 1459173

Group type: EXPERIMENTAL
Intervention: n‐3 polyunsaturated fatty acids (n‐3 PUFA) supplementation (3.6 g, 12 weeks)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo (six capsules with fat composition as the average Danish diet)
Number of subjects: 51
Study: 3881418

Group type: EXPERIMENTAL
Intervention: Trimipramine
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 31400177

Group type: EXPERIMENTAL
Intervention: Qualitative research alongside RCTs focusing on illicit drug use
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Temporal parallel purpose framework
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Qualitative research
Number of subjects: 0
Study: 29718171

Group type: EXPERIMENTAL
Intervention: NHS AKI e-alerts
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Educational outreach programme
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Combined interventions (e-alerts and educational outreach)
Number of subjects: 251
Study: 27021751

Group type: EXPERIMENTAL
Intervention: IVR
Number of subjects: 21752

Group type: EXPERIMENTAL
Intervention: IVR+
Number of subjects: 21752

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 21752

Group type: EXPERIMENTAL
Intervention: IVR-based interventions
Number of subjects: 21752
Study: 24951468

Group type: EXPERIMENTAL
Intervention: Kids' ITP Tools parent self-report score for recovered patients (n=69)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Kids' ITP Tools parent self-report score for patients with persistent disease (n=21)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Health-related quality of life scores between children with mild or moderate bleeding
Number of subjects: 107

Group type: COMPARATOR
Intervention: Health-related quality of life scores between children who received intravenous immunoglobulin and those who were carefully observed
Number of subjects: 107
Study: 22150819

Group type: COMPARATOR
Intervention: No supervision
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Twice weekly supervision
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Daily supervision
Number of subjects: 60
Study: 19130298

Group type: EXPERIMENTAL
Intervention: Mitoxantrone plus prednisone (M + P)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Docetaxel plus estramustine (D + E)
Number of subjects: 0
Study: 17268413

Group type: EXPERIMENTAL
Intervention: Flaxseed oil (8 g/day)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Safflower oil (11 g/day linoleic acid)
Number of subjects: 59
Study: 15703464

Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg + acetylsalicylic acid (ASA) 75 mg daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: ASA 75 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Extended-release dipyridamole 200 mg/low‐dose ASA 25 mg twice daily
Number of subjects: 0
Study: 12075263

Group type: EXPERIMENTAL
Intervention: Transmyocardial revascularization (TMR)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Percutaneous laser revascularization (PTMR)
Number of subjects: 401

Group type: COMPARATOR
Intervention: Medical therapy (MED(TMR) and MED(PTMR))
Number of subjects: 401
Study: 9584297

Group type: EXPERIMENTAL
Intervention: Upper rate programmed to 220-age
Number of subjects: 11

Group type: COMPARATOR
Intervention: Upper rate programmed to 120 beats/min
Number of subjects: 11
Study: 7659199

Group type: EXPERIMENTAL
Intervention: Isoflurane narcotherapy (ISONAR)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Electroconvulsive treatment (ECT)
Number of subjects: 20
Study: 2539838

Group type: EXPERIMENTAL
Intervention: Fish oil (containing EPA and DHA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fish oil (EPA and DHA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ALA supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preformed EPA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EPA or DHA supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supplements containing DHA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (olive oil)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 18116

Group type: EXPERIMENTAL
Intervention: Oral bucolome (30 mg/kg per day for 5 days)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no bucolome)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Oral bucolome
Number of subjects: 50
Study: 31112406

Group type: EXPERIMENTAL
Intervention: 15 g of milk protein concentrate (MPC80) with 1.5 g of free leucine (15G+LEU)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 15 g of milk protein concentrate (MPC80) without leucine (15G)
Number of subjects: 24
Study: 29300110

Group type: EXPERIMENTAL
Intervention: Pharmacist-provided information booklet
Number of subjects: 160

Group type: COMPARATOR
Intervention: Conventional counselling (control group)
Number of subjects: 160
Study: 26012639

Group type: EXPERIMENTAL
Intervention: Intra-arterial treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous tissue-type plasminogen activator alone
Number of subjects: 0
Study: 23952326

Group type: EXPERIMENTAL
Intervention: Insulin degludec
Number of subjects: 1023

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 1023
Study: 20650976

Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention consisting of 12 manual‐based informative sessions on schizophrenia
Number of subjects: 219

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 219
Study: 19377494

Group type: EXPERIMENTAL
Intervention: Left atrial catheter ablation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pharmacological therapies
Number of subjects: 0
Study: 18007083

Group type: EXPERIMENTAL
Intervention: Traditional tidal volume ventilation (10 mL/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low tidal volume ventilation (6 mL/kg)
Number of subjects: 20
Study: 14670310

Group type: EXPERIMENTAL
Intervention: Adult-type dTpa booster vaccine (Boostrix)
Number of subjects: 0
Study: 11922111

Group type: EXPERIMENTAL
Intervention: CAR
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: CAF+CAR
Number of subjects: 5

Group type: COMPARATOR
Intervention: CON
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: CAF
Number of subjects: 5
Study: 9701196

Group type: EXPERIMENTAL
Intervention: Chinese diet (high-starch, low-fat)
Number of subjects: 12
Study: 7722345

Group type: EXPERIMENTAL
Intervention: gemfibrozil
Number of subjects: 395
Study: 2680678

Group type: EXPERIMENTAL
Intervention: Controlled release salbutamol 8 mg twice daily
Number of subjects: 68

Group type: COMPARATOR
Intervention: Aminophylline 525 or 700 mg twice daily
Number of subjects: 68
Study: 577226

Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Non-prophylactic cranial irradiation (non-PCI)
Number of subjects: 29
Study: 31201653

Group type: EXPERIMENTAL
Intervention: Brief cognitive behavioral therapy (bCBT) with physical health module
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Brief cognitive behavioral therapy (bCBT)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Enhanced usual care condition
Number of subjects: 127
Study: 29393237

Group type: EXPERIMENTAL
Intervention: HFNC
Number of subjects: 272

Group type: COMPARATOR
Intervention: nCPAP
Number of subjects: 272
Study: 26897552

Group type: EXPERIMENTAL
Intervention: Familiar game (Solitaire)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Novel game (Bubble Xplode)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both games (Familiar and Novel)
Number of subjects: 30
Study: 25056504

Group type: EXPERIMENTAL
Intervention: 20% human albumin
Number of subjects: 44

Group type: COMPARATOR
Intervention: 0.9% normal saline
Number of subjects: 44
Study: 22468908

Group type: EXPERIMENTAL
Intervention: Telephone-administered cognitive-behavioral therapy (T-CBT)
Number of subjects: 46
Study: 20733446

Group type: EXPERIMENTAL
Intervention: Daily text-message reminders
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (no reminders)
Number of subjects: 82
Study: 18026999

Group type: COMPARATOR
Intervention: Laparoscopic surgery
Number of subjects: 177

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 177

Group type: COMPARATOR
Intervention: Coloanal anastomotic techniques
Number of subjects: 177

Group type: COMPARATOR
Intervention: Other surgical techniques
Number of subjects: 177
Study: 16170973

Group type: EXPERIMENTAL
Intervention: ID/flossette (ID/F)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: ID/pick (ID/P)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Manual dental floss
Number of subjects: 84
Study: 12066206

Group type: EXPERIMENTAL
Intervention: LCAH concomitant with cisplatin
Number of subjects: 81

Group type: COMPARATOR
Intervention: LCAH alone
Number of subjects: 81
Study: 10555659

Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 8867483

Group type: EXPERIMENTAL
Intervention: Laparoscopic intervention
Number of subjects: 193

Group type: COMPARATOR
Intervention: Conventional intervention
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 193

Group type: COMPARATOR
Intervention: Traditional operative method
Number of subjects: 193
Study: 1955620

Group type: EXPERIMENTAL
Intervention: Diet with 30% calories from fat, 300 mg cholesterol/day
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Diet with 26% calories from fat, 200 mg cholesterol/day
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Diet with 22% calories from fat, 100 mg cholesterol/day
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Diet with 18% calories from fat, 100 mg cholesterol/day
Number of subjects: 531
Study: 7035950

Group type: EXPERIMENTAL
Intervention: Methotrexate alone
Number of subjects: 67

Group type: COMPARATOR
Intervention: Methotrexate, antithymocyte globulin, and prednisone
Number of subjects: 67
Study: 30813188

Group type: EXPERIMENTAL
Intervention: 0.025% BAC
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 0.05% BAC
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 0.09% BAC
Number of subjects: 24

Group type: COMPARATOR
Intervention: 0% BAC (placebo)
Number of subjects: 24
Study: 30127596

Group type: EXPERIMENTAL
Intervention: Milnacipran 100 mg
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 27179724

Group type: EXPERIMENTAL
Intervention: STEMI
Number of subjects: 8859

Group type: EXPERIMENTAL
Intervention: NSTE-ACS
Number of subjects: 8859

Group type: COMPARATOR
Intervention: SIHD
Number of subjects: 8859
Study: 24596459

Group type: EXPERIMENTAL
Intervention: IND + GLY (indacaterol 150 μg and glycopyrronium 50 μg daily)
Number of subjects: 449

Group type: COMPARATOR
Intervention: IND + PBO (indacaterol 150 μg daily and placebo)
Number of subjects: 449
Study: 22578727

Group type: EXPERIMENTAL
Intervention: Adjuvant androgen deprivation therapy
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: pT3b disease with positive surgical margins at the bladder neck
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: pT3a disease (regardless of positive surgical margin location and lymph node invasion) and pT3b tumors with negative bladder neck margins
Number of subjects: 173
Study: 19816216

Group type: EXPERIMENTAL
Intervention: Unilateral upper‐body resistance exercise (RE) protocol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bilateral upper‐body resistance exercise (RE) protocol
Number of subjects: 10
Study: 18066133

Group type: EXPERIMENTAL
Intervention: NG440 (a combination of rho iso-alpha acids from hops, rosemary, and oleanolic acid)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NG440
Number of subjects: 0
Study: 12793922

Group type: EXPERIMENTAL
Intervention: Inspiratory time (25%, 33%, 50%, and 67% of the respiratory cycle)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Inspiratory time (increasing)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Inspiratory time (very low <0.4 secs and very long >1.0 secs)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Inspiratory time (0.4-1.0 secs)
Number of subjects: 15
Study: 10210394

Group type: EXPERIMENTAL
Intervention: 2 mg tolterodine
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: 1 mg tolterodine
Number of subjects: 316

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 316
Study: 7790604

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO) at 18 ppm
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Infusion of prostacyclin (PGI2) at 4 ng.kg-1.min-1
Number of subjects: 10
Study: 2088632

Group type: EXPERIMENTAL
Intervention: Silica-based toothpaste containing strontium acetate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Silica-based toothpaste containing strontium acetate and MFP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Commercially available formaldehyde-containing toothpaste
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diatomaceous earth/strontium chloride toothpaste
Number of subjects: 0
Study: 6117536

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Mesoridazine
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Dysphoric response to neuroleptics
Number of subjects: 39
Study: 31455710

Group type: EXPERIMENTAL
Intervention: PRO‐based symptom management with alerts when symptom scores reach ≥4
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard procedures for symptom management (Control)
Number of subjects: 160
Study: 26445404

Group type: EXPERIMENTAL
Intervention: Up-front incentive payment (supermarket cash voucher of HD$50)
Number of subjects: 720

Group type: COMPARATOR
Intervention: Delayed incentive payment (voucher sent after 1-year follow-up)
Number of subjects: 720
Study: 23372361

Group type: EXPERIMENTAL
Intervention: Acu-TENS
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo-TENS
Number of subjects: 40
Study: 22368874

Group type: EXPERIMENTAL
Intervention: Reduning injection plus antibiotics and basic therapy
Number of subjects: 7
Study: 19828532

Group type: EXPERIMENTAL
Intervention: Interleukin-2 plus antiretroviral therapy (SILCAAT)
Number of subjects: 5806

Group type: EXPERIMENTAL
Intervention: Interleukin-2 plus antiretroviral therapy (ESPRIT)
Number of subjects: 5806

Group type: COMPARATOR
Intervention: Antiretroviral therapy alone (SILCAAT)
Number of subjects: 5806

Group type: COMPARATOR
Intervention: Antiretroviral therapy alone (ESPRIT)
Number of subjects: 5806
Study: 19650964

Group type: EXPERIMENTAL
Intervention: Nutrition education intervention in kindergartens (monthly activities for children and parents)
Number of subjects: 2102

Group type: EXPERIMENTAL
Intervention: Nutrition education intervention in kindergartens
Number of subjects: 2102

Group type: COMPARATOR
Intervention: Control group (no nutrition education)
Number of subjects: 2102
Study: 15605372

Group type: EXPERIMENTAL
Intervention: Self-completed postal questionnaire reporting urinary symptoms
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Self-reported urinary symptoms (SI and UI)
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Self-reported urinary symptoms (DO related symptoms)
Number of subjects: 488
Study: 12060416

Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 0

Group type: COMPARATOR
Intervention: Droperidol
Number of subjects: 0
Study: 10543291

Group type: EXPERIMENTAL
Intervention: Exposure to benzene (1 microg x m3 air)
Number of subjects: 5421

Group type: EXPERIMENTAL
Intervention: Exposure to NO2 and CO
Number of subjects: 5421

Group type: EXPERIMENTAL
Intervention: Exposure to traffic-related air pollution
Number of subjects: 5421
Study: 7852670

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium 4 mg four times daily
Number of subjects: 212

Group type: COMPARATOR
Intervention: Albuterol 180 micrograms four times daily
Number of subjects: 212
Study: 2161310

Group type: EXPERIMENTAL
Intervention: Computer program for sample size and power calculations
Number of subjects: 0
Study: 111873

Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate
Number of subjects: 10
Study: 12460877

Group type: EXPERIMENTAL
Intervention: Phenylephrine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Esmolol
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Phenylephrine in low-flow POTS subgroup
Number of subjects: 14
Study: 31925809

Group type: EXPERIMENTAL
Intervention: Statin therapy (STA trial)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (PLAC trial)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Exercise plus placebo (EXER+PLAC trial)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Exercise plus statin (EXER+STA trial)
Number of subjects: 10
Study: 29727777

Group type: EXPERIMENTAL
Intervention: Individuals with 1st MTPJ OA
Number of subjects: 20
Study: 26749529

Group type: EXPERIMENTAL
Intervention: Teneligliptin (20mg)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study: 25012497

Group type: EXPERIMENTAL
Intervention: Nobori biolimus-eluting stent (BES)
Number of subjects: 9114
Study: 22249833

Group type: EXPERIMENTAL
Intervention: PRS-15 sequence (pseudo-randomized sequence, mean ISI of 15 s)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard sequence (ISI of 30 s)
Number of subjects: 40
Study: 20304051

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (4000 IU vitamin D3 daily for 6 months)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo (not supplemented)
Number of subjects: 81
Study: 18538098

Group type: EXPERIMENTAL
Intervention: Polysulphone (PS) membrane
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cellulose triacetate (CTA) membrane
Number of subjects: 20

Group type: COMPARATOR
Intervention: Polyester‐polymer alloy (PEPA) membrane
Number of subjects: 20
Study: 16044844

Group type: EXPERIMENTAL
Intervention: Hitamine (enterosorbent of marine origin) combined with dietotherapy
Number of subjects: 0
Study: 11828240

Group type: EXPERIMENTAL
Intervention: 8 g NH(4)Cl acute administration
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Subjects with a history of stress fractures
Number of subjects: 29

Group type: COMPARATOR
Intervention: Subjects without a history of stress fractures
Number of subjects: 29
Study: 10088991

Group type: EXPERIMENTAL
Intervention: Substitute (sugar and coloring)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Continuation of coffee
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Prenatal coffee ingestion
Number of subjects: 132
Study: 7751874

Group type: EXPERIMENTAL
Intervention: 5-FU plus IFN (10 MU subcutaneously three times weekly)
Number of subjects: 106

Group type: COMPARATOR
Intervention: 5-FU alone (750 mg/m2/d by continuous infusion for 5 consecutive days followed by weekly bolus 5-FU 750 mg/m2)
Number of subjects: 106
Study: 2281582

Group type: EXPERIMENTAL
Intervention: 75 ml of ioversol (Optiray-320)
Number of subjects: 120

Group type: COMPARATOR
Intervention: 100 ml of diatrizoate (Renografin-60)
Number of subjects: 120
Study: 382393

Group type: EXPERIMENTAL
Intervention: Meptazinol 100 mg intramuscularly
Number of subjects: 50

Group type: COMPARATOR
Intervention: Omnopon 20 mg intramuscularly
Number of subjects: 50
Study: 31723037

Group type: EXPERIMENTAL
Intervention: Heat-stable microparticle platform for oral micronutrient delivery (BMC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Micronutrient encapsulation (11 micronutrients including iron, iodine, zinc, vitamins A, B2, niacin, biotin, folic acid, B12, C, and D)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Initial human study of iron bioavailability from microparticles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Organotypic human intestinal model
Number of subjects: 0
Study: 29429177

Group type: EXPERIMENTAL
Intervention: Planned neck dissection (PND) + concurrent chemoradiotherapy (CCRT)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Concurrent chemoradiotherapy (CCRT)
Number of subjects: 64
Study: 26700214

Group type: EXPERIMENTAL
Intervention: H-100
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: H-100 (after crossover from placebo)
Number of subjects: 22